Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Zura Bio ( (ZURA) ).
On January 12, 2026, Zura Bio Limited released an updated corporate presentation and a press release detailing corporate and clinical trial developments, including its outlook for 2026. The company highlighted ongoing Phase 2 studies of its lead dual-pathway antibody tibulizumab in hidradenitis suppurativa and systemic sclerosis, noted expected topline data readouts in late 2026 and the first half of 2027, and emphasized that its current cash position of $139 million as of September 30, 2025 is expected to support operations through 2027, underscoring its funding runway through key clinical milestones.
The most recent analyst rating on (ZURA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum (price above key moving averages with positive MACD). Corporate events are a modest positive due to the cleanup/reset of agreements and related risk reduction, while valuation is difficult to assess given the negative P/E and no dividend yield data.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company focused on developing differentiated therapies for complex immune and autoimmune disorders. Its lead candidate, tibulizumab, is a first-in-class bispecific antibody that simultaneously targets IL-17 and BAFF pathways, with an initial clinical focus on hidradenitis suppurativa and systemic sclerosis, and the company reports having sufficient cash to fund planned operations through 2027.
Average Trading Volume: 583,404
Technical Sentiment Signal: Buy
Current Market Cap: $342M
Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.